These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 10659399)

  • 1. Itasetron. DAU 6215, U 98079.
    Drugs R D; 1999 Oct; 2(4):243-4. PubMed ID: 10659399
    [No Abstract]   [Full Text] [Related]  

  • 2. Zatosetron. LY 191617, LY 277359.
    Drugs R D; 1999 Oct; 2(4):253-5. PubMed ID: 10659404
    [No Abstract]   [Full Text] [Related]  

  • 3. Lerisetron. F 0930, F 0930RS.
    Drugs R D; 1999 Oct; 2(4):245-6. PubMed ID: 10659400
    [No Abstract]   [Full Text] [Related]  

  • 4. Palonosetron. RS 25259, RS 25259 197.
    Drugs R D; 1999 Oct; 2(4):251-2. PubMed ID: 10659403
    [No Abstract]   [Full Text] [Related]  

  • 5. Ramosetron, a 5-HT3 receptor antagonist for the control of nausea and vomiting.
    Rabasseda X
    Drugs Today (Barc); 2002 Feb; 38(2):75-89. PubMed ID: 12532186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of oral itasetron with oral ondansetron: results of a double-blind, active-controlled phase II study in chemotherapy-naive patients receiving moderately emetogenic chemotherapy.
    Goldschmidt H; Salwender H; Egerer G; Kempe R; Voigt T
    Anticancer Drugs; 1997 Jun; 8(5):436-44. PubMed ID: 9215605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacology and clinical experiences with serotonin (5-HT3) receptor antagonists].
    Scholz J
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1997 Oct; 32(10):626-8. PubMed ID: 9445561
    [No Abstract]   [Full Text] [Related]  

  • 8. LAS 30451: a novel 5-HT3 antagonist.
    Martin M; Rosell R; Guillem V; Díaz-Rubio E; Moreno I; Soriano V; Fernández A; Pérez A
    Eur J Cancer; 1993; 29A Suppl 1():S33-4. PubMed ID: 8427723
    [No Abstract]   [Full Text] [Related]  

  • 9. Anticipatory nausea and vomiting in the era of 5-HT3 antiemetics.
    Morrow GR; Roscoe JA; Kirshner JJ; Hynes HE; Rosenbluth RJ
    Support Care Cancer; 1998 May; 6(3):244-7. PubMed ID: 9629877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Granisetron vs ondansetron: is it a question of duration of 5-HT3 receptor blockade?
    Blower P; Aapro M
    Br J Cancer; 2002 May; 86(10):1662-3; author reply 1664. PubMed ID: 12085221
    [No Abstract]   [Full Text] [Related]  

  • 11. [From cocaine to innovative antiemetics. The medicinal chemistry of 5-ht3 receptor antagonists].
    Zettl H; Schubert-Zsilavecz M; Siebert CD
    Pharm Unserer Zeit; 2007; 36(5):354-61. PubMed ID: 17722162
    [No Abstract]   [Full Text] [Related]  

  • 12. Antiemetic strategies for high-dose chemoradiotherapy-induced nausea and vomiting.
    Spitzer TR; Grunberg SM; Dicato MA
    Support Care Cancer; 1998 May; 6(3):233-6. PubMed ID: 9629875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zatosetron. (LY 191617, LY 277359).
    Drugs R D; 1999 Dec; 2(6):397-9. PubMed ID: 10763451
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparative efficacy and safety of palonosetron with the first 5-HT3 receptor antagonists for the chemotherapy-induced nausea and vomiting: a meta-analysis.
    Jin Y; Sun W; Gu D; Yang J; Xu Z; Chen J
    Eur J Cancer Care (Engl); 2013 Jan; 22(1):41-50. PubMed ID: 22519361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy.
    Gregory RE; Ettinger DS
    Drugs; 1998 Feb; 55(2):173-89. PubMed ID: 9506240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prevention and treatment of postoperative nausea and postoperative vomiting with tropisetron].
    Hennes HJ
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1997 Oct; 32(10):628-31. PubMed ID: 9445562
    [No Abstract]   [Full Text] [Related]  

  • 17. Antiemetic activity of the new 5-HT3 antagonist DAU 6215 in animal models of cancer chemotherapy and radiation.
    Sagrada A; Turconi M; Bonali P; Schiantarelli P; Micheletti R; Montagna E; Nicola M; Algate DR; Rimoldi EM; Donetti A
    Cancer Chemother Pharmacol; 1991; 28(6):470-4. PubMed ID: 1834359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unusual reactions to 5-HT3 receptor antagonists in a child with rhabdomyosarcoma.
    Lee CY; Ratnapalan S; Thompson M; Nathan PC; Closs J; French A; Punnett A; Garcia-Bournissen F; Ito S; Koren G
    Can J Clin Pharmacol; 2010; 17(1):e1-4. PubMed ID: 20051608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal selection of antiemetics in children receiving cancer chemotherapy.
    Roila F; Aapro M; Stewart A
    Support Care Cancer; 1998 May; 6(3):215-20. PubMed ID: 9629872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5-HT3-receptor antagonists in the control of delayed-onset emesis.
    Gridelli C
    Anticancer Res; 2003; 23(3C):2773-82. PubMed ID: 12926112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.